Stem Cell Therapy for Rheumatoid Arthritis

Terapi Sel Punca untuk Artritis Reumatoid

Rheumatoid arthritis is an autoimmune disease in which the body's immune system attacks the joints.

While pharmacological therapies have advanced considerably in recent years, many patients can achieve symptom control or remission. However, it remains challenging to cure the disease itself, and it is impossible to restore damaged joints to their original state.

Current challenges arise from immunosuppressive treatments posing a risk of adverse effects and existing therapies demonstrating insufficient efficacy for some patients. Against this backdrop, Stem Cell Therapy is attracting significant interest as a novel regenerative therapy.

Stem cell therapy is an unprecedented approach that not only normalizes an out-of-balance immune system but also promotes the regeneration of damaged tissues, bringing new hope for addressing rheumatoid arthritis.

Rheumatoid Arthritis: What Is It? Current Treatment Methods and Remaining Challenges

Rheumatoid arthritis is a disease that causes joint damage and functional impairment if it progresses, and recovery is difficult with existing treatments, so new treatment methods are needed.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. In Japan, approximately 1% of the population (1 in 100 individuals) is estimated to be affected by this condition, and it is particularly prevalent among women.

The primary symptoms are joint pain, swelling, and stiffness, with characteristic morning stiffness occurring upon waking. If inflammation persists, cartilage and bone will erode, leading to joint deformity and restricted range of motion.

Should it progress, the digits may become permanently flexed and irreducible, or joint deformity may occur, leading to significant functional impairment in daily life.

This functional impairment caused by joint damage significantly reduces patients' quality of life (QOL), and in severe cases, can make maintaining employment challenging or require care.

Current Major Pharmacological Therapies and Clinical Outcomes

To date, in the treatment of rheumatoid arthritis, anti-inflammatory drugs (pain relievers), methotrexate (MTX) and other conventional disease-modifying anti-rheumatic drugs, as well as biological agents (e.g., anti-TNFα antibodies, IL-6 receptor inhibitors), have been employed.

Since the 1990s, with the advent of MTX and biological agents, therapeutic outcomes have dramatically improved, and rheumatoid arthritis has transformed from an "incurable disease" into a disease amenable to remission with treatment.

For example, in a 1-year clinical trial administering the biological agent infliximab, approximately 38% of patients achieved remission or low disease activity, and 58% of patients were able to halt the progression of joint damage.

Through the early and appropriate administration of pharmacotherapy, many patients are now able to achieve significant symptomatic improvement.

Unresolved Challenges

However, currently available therapeutic drugs have not achieved a complete cure. While these medications can suppress inflammation, it remains challenging to fundamentally eliminate the autoimmune cause itself, and there are no treatment methods to restore already damaged joints to their original condition.

Although the progression of joint damage can be arrested, damaged cartilage and bone do not naturally regenerate. Consequently, for patients who have long suffered from this disease and accumulated severe joint damage, functional impairment may still persist, even with the most advanced pharmacological therapies.

Furthermore, given that current primary pharmacological therapies suppress immune function, there is a risk of side effects such as infection, which complicates the continuation of treatment. Nevertheless, it is reported that 20-40% of patients (with some reports indicating up to 50%) do not achieve sufficient efficacy from existing treatments.

In this way, the challenge of treating rheumatoid arthritis iscompletely stopping immune success and repairing damaged jointsIt still remains, and a new approach to resolve this has been requested.

Key Point

  • Chronic inflammation occurs in the joints due to an immune disorder.
  • As cartilage and bone damage progresses, joint function declines, and quality of life (QOL) is impaired.
  • Traditional pharmacological therapy may be aimed at symptom remission, but a cure is difficult.
  • Risks of adverse effects from immunosuppression and instances of insufficient efficacy also exist, thus necessitating novel therapeutic approaches.

New Possibilities in Regenerative Therapy: Why Stem Cell Therapy is Gaining Attention

Stem Cell Therapy for rheumatoid arthritis is a next-generation regenerative therapy that normalizes immune abnormalities while targeting joint tissue repair.

In recent years, Stem Cell Therapy has garnered attention as a revolutionary treatment method for rheumatoid arthritis.

Stem Cell Therapy is a medical treatment method that involves taking stem cells from the patient or a donor and introducing them into the body, leveraging their regenerative capacity and immunomodulatory properties to improve the patient's condition. By gently normalizing immune abnormalities, promoting the repair and regeneration of damaged tissues, and demonstrating therapeutic effects through various mechanisms such as inflammation suppression and paracrine effects (intercellular signal transduction), it is gaining attention as a multi-functional regenerative therapy.

Numerous types of stem cells exist, but mesenchymal stem cells (MSCs) have attracted considerable interest for rheumatoid arthritis. MSCs are found in bone marrow, adipose tissue, the umbilical cord, and other sources. They not only possess the capacity to differentiate into bone and cartilage but are also endowed with immunomodulatory functions that can normalize aberrant immune responses.

For this reason, rather than merely suppressing the immune system, by gently modulating excessive immune reactions, a fundamental improvement in rheumatoid arthritis is anticipated. Furthermore, since MSCs also promote the repair and regeneration of damaged cartilage and bone, this offers a significant advantage as it can address both the cause of rheumatoid arthritis (immune dysfunction) and its consequences (joint damage).

Based on these characteristics, MSCs are recognized as a next-generation therapeutic strategy that addresses both "attack" (via regeneration) and "defense" (via adaptation), with ongoing research and application worldwide.

What are the advantages of MSCs derived from Wharton's Jelly?

MSCs are primarily extracted from adipose tissue, bone marrow, umbilical cord (Wharton's jelly), among other sources. Among these, bone marrow-derived MSCs (BM-MSCs), which were formerly the mainstream, pose a significant burden on the body associated with their extraction, and the yield of extractable cells is limited. Consequently, they are considered to present numerous challenges.

Conversely, umbilical cord-derived Wharton's Jelly mesenchymal stem cells (WJ-MSCs), naturally acquired at birth, are highly valued due to their non-invasive acquisition method, which involves no associated pain or risk, and their ethical acceptability as a cell source.

Furthermore, it has been demonstrated that umbilical cord-derived Mesenchymal Stem Cells (MSCs) possess immunomodulatory and differentiation capacities comparable to those derived from bone marrow. Additionally, as the cells themselves are young and exhibit superior proliferative capacity, there is the advantage that high-quality cells can be readily and stably supplied.

Given these characteristics, umbilical cord-derived MSCs have garnered attention as a promising option for applications in immune and inflammatory diseases, including rheumatoid arthritis.

Key Point

  • Stem Cell Therapy is a versatile treatment modality that leverages its regenerative capacity and immunomodulatory effects.
  • Mesenchymal stem cells (MSCs) hold significant promise, particularly for rheumatoid arthritis, an autoimmune disease.
  • MSCs gently normalize immune abnormalities while promoting cartilage and bone regeneration.
  • Umbilical cord-derived MSCs can be harvested non-invasively, providing high-quality and stable cells.
  • Umbilical cord-derived MSCs are comparable to those from bone marrow in terms of immunomodulatory potential and differentiation capacity, and are garnering interest as a promising future therapeutic option.
Tentang Sel Punca Wharton's Jelly
Learn More

How Stem Cell Therapy Works in Rheumatoid Arthritis: 3 Mechanisms of Action

Stem cells (MSCs) act in a multi-faceted manner in rheumatoid arthritis through three actions: immune modulation, inflammation suppression, and joint repair.

Mesenchymal Stem Cells (MSCs) are understood to exert their effects on rheumatoid arthritis through a tripartite mechanism: normalizing aberrant autoimmune responses, suppressing joint inflammation via potent anti-inflammatory action, and promoting the repair of damaged cartilage and bone.

In contrast to traditional pharmaceutical agents that primarily focus on the symptomatic suppression of inflammation, MSC modulates the immune system directly, fundamentally resolving inflammation and further promoting tissue regeneration, which constitutes a significant breakthrough in this field.

Normalisasi Keseimbangan Imun
─ Brake on a Runaway Immune Response

In rheumatoid arthritis, the normally protective immune system becomes dysregulated and attacks the patient's own joints. Mesenchymal Stem Cells (MSCs) act to attenuate this aberrant immune response and restore immune homeostasis.

Specifically, it is known to suppress the overactivity of pro-inflammatory T-cells (such as Th17 and Th1 cells) and enhance the function of immunosuppressive regulatory T-cells (Treg cells).

Furthermore, it also acts on antibody-producing B cells and is reported to reduce the production of autoantibodies, which are the cause of rheumatoid arthritis.

In this way, MSCs function as a "modulator" that calms the immune system in a state of heightened activity and restores it to a normal condition.Facing a car speeding with broken brakes, MSC braked and restored its speed.──itulah imajnya.

Potent Anti-Inflammatory Action
─ Penenangan Peradangan oleh Sitokin

MSCs also possess anti-inflammatory actions by secreting cytokines and growth factors. These secretions are collectively termed the "secretome" and directly act on excessive immune reactions within the joints.

For example, interleukin 10 (IL-10), prostaglandin E2 (PGE2), TGF-β, and other factors secreted by MSCs suppress the production of pro-inflammatory cytokines and disrupt the self-perpetuating inflammatory cycle within the joint.

This type of work is called "paracrine effect (paracrine secretion)" and is one of the important mechanisms of MSC therapy.

Sederhananya, MSC memainkan peran "agen pemadam kebakaran" menenangkan api peradangan, and through this, the envisaged outcome is the reduction of joint pain and swelling.

Promosi Perbaikan Jaringan
Helps regenerate damaged cartilage and bone.

MSCs possess the ability to promote the repair and regeneration of damaged joint tissue. As needed, MSCs themselves can differentiate into chondrocytes or osteoblasts, or secrete growth factors that aid in the regeneration of surrounding cells, supporting structural joint recovery.

In rheumatoid arthritis, cartilage and bone are destroyed by inflammation, but MSCs have the potential to aid their regeneration.

Studies have confirmed that umbilical cord-derived MSCs, when cultured under conditions suitable for cartilage formation, produce significant amounts of collagen and proteoglycans—key components of articular cartilage—and are capable of differentiating into mature chondrocytes.

Furthermore, because it also releases factors that promote bone formation, it is expected to be useful in the repair of bone defects. In other words,MSC can also play a role in helping to repair damaged joint tissue..

As described above, MSCs modulate immune dysregulation (addressing the underlying cause), suppress inflammation, and regenerate tissue (addressing the outcome) through these multifaceted actions, thereby comprehensively targeting the pathology of rheumatoid arthritis itself.

Given these unique characteristics, it is hoped to pave the way for a fundamental treatment for rheumatoid arthritis, which traditional therapies have been unable to achieve.

Key Point

  • MSC modulates overactive immune responses and suppresses autoimmune-mediated joint damage.
  • Releasing anti-inflammatory substances and mitigating joint inflammation at its source.
  • Releasing factors that promote the regeneration of cartilage and bone, thereby contributing to tissue repair.
  • It is characterized by addressing both the cause (immune disorders) and the effects (tissue damage).

Spesialis Reumatik /
Dr. Itakura from Chiba Physical Rehabilitation Center

Dr. Itakura, who has extensive knowledge and experience in rheumatology and shares a lot of content on YouTube, is pleased to collaborate with 23Century in Stem Cell Therapy.
Trusted by many people in their daily activities, this is a very reliable partner.

Tentang YouTube Dr. Itakura
Learn More

Clinical Trials in Refractory Rheumatoid Arthritis Demonstrated Anticipated Therapeutic Effects of MSC Therapy.

Even in rheumatoid arthritis that is difficult to treat with traditional medicine, Stem Cell Therapy (MSC) is safe, and symptom improvement and inflammation suppression are expected.

Even in patients with rheumatoid arthritis (RA) refractory to prior treatments, Mesenchymal Stem Cell (MSC) Therapy has been reported to demonstrate a high safety profile and promising effects on symptom improvement and suppression of inflammation, in both domestic and international clinical trials.

Even in instances where conventional therapies proved inadequate, swelling and joint pain have been alleviated through treatment with MSCs, disease progression has been suppressed, and such cases have been documented.

Placebo-Controlled MSC Trial

A verification trial of MSC treatment effects was conducted on 53 patients with rheumatoid arthritis refractory to conventional drug therapy. In the MSC-treated group, joint inflammation and pain were reduced, and no specific adverse events were reported.

At the 3-month post-treatment mark, the proportion of individuals with significantly reduced disease activity was also high. This is highly regarded as a clinical trial for the "initial verification stage" to confirm the presence or absence of an effect.

Large-Scale MSC Clinical Trials

In a large-scale clinical trial involving 172 participants, improvements were observed in joint condition and inflammatory markers (including CRP and erythrocyte sedimentation rate). Furthermore, no safety concerns were identified.

Notably, instances have been reported where favorable conditions were maintained for 8 months to a maximum of 3 years following a single injection, and a sustained effect is anticipated.

Trial of MSC Treatment in Early-Stage Rheumatic Patients

In an early-phase clinical trial of MSC treatment for rheumatoid arthritis patients, safety was confirmed, and a tendency to suppress disease progression was also observed.

By introducing treatment at a stage before joint destruction, its preventative effects also warrant attention.

This clinical trial demonstrated that Mesenchymal Stem Cell (MSC) therapy offers new promise for rheumatoid arthritis refractory to conventional treatments.

Reduced joint inflammation, alleviated pain, or halted disease progression reportedly enables patients to experience a more comfortable daily life. The observation of virtually no side effects also provides substantial reassurance for many patients.

Future research will further investigate the optimal recipients and timing for injections, with the aim of developing a more accessible, safe, and practical treatment method for a broader population.

Key Point

  • MSC therapy demonstrates efficacy in rheumatoid arthritis patients who are refractory to conventional treatments.
  • In placebo-controlled and large-scale trials, increases in joint inflammation, pain, and disease activity have been reported.
  • In the treatment of early-stage disease, the suppression of disease progression and the prevention of joint damage are also anticipated.

Stem Cell Therapy Safety: Concerning Adverse Event Risks?

Stem Cell Therapy has been evaluated as having high safety in research to date, and there have been almost no reports of serious side effects.

For Stem Cell Therapy (MSC therapy) in rheumatoid arthritis, numerous clinical trials conducted both nationally and internationally have reported virtually no serious adverse events, and it is considered a therapeutic approach with a high safety profile.

Even within a global meta-analysis integrating and analyzing multiple studies, no significant difference was found in the incidence of adverse events between the MSC treatment group and the control group. It was concluded that the risk is not specifically elevated compared to traditional treatments.

Furthermore, even in clinical trials where 800 million MSCs, a dose substantially exceeding typical levels, were administered in a single injection, no serious adverse events were reported, suggesting the potential for safe application within a broad dosage spectrum.

The reasons MSC is considered safe.

The high safety of MSCs comes from their biological characteristics. MSCs have low expression of HLA antigens (human leukocyte antigens) on the cell surface, so even if cells originating from another person, within the body, they are easily recognized by the immune system andRejection is unlikely. terjadi.

These characteristics enable MSCs sourced from healthy donors, beyond the patient's autologous cells, to be safely applied for treatment.

Furthermore, unlike embryonic stem cells (ES cells) that abnormally proliferate and form tumors (teratomas), MSCs carry no risk of tumor formation, which is a significant advantage. Moreover, previous animal experiments have confirmed no tumor formation or serious toxicity, even when a large number of MSCs were transplanted long-term.

Stem Cell Therapy undoubtedly requires stringent safety measures, such as quality control and infection testing, as prerequisites. Nevertheless, the inherent nature of the cells themselves confers a high safety profile, which is a significant advantage for regenerative therapy.

"This is a new treatment, so I'm worried." There's also a sound like that, but from what is known so far,MSC therapy for rheumatoid arthritis is also a quite reliable treatment option in terms of safety.It can be said.

Key Point

  • Clinical trials of MSC treatment for rheumatoid arthritis have reported almost no serious side effects.
  • In placebo-controlled comparative trials, no significant safety differences were observed, and no adverse reactions were reported beyond minor ones.
  • In the meta-analysis, compared to conventional therapy, no specific risk was identified.
  • MSC have low HLA antigen expression, and rejection reactions are unlikely, so they can be injected without immunosuppressive agents.
  • The absence of tumor formation risk, encompassing the inherent high safety of the cell itself, is a key feature.

Recent Advances: The Evolving Future of Regenerative Therapy in Rheumatoid Arthritis Treatment

Stem cell therapy for rheumatoid arthritis represents a promising new treatment modality capable of addressing challenges inadequately managed by current therapies. Through its unique mechanism of action, which normalizes immune function while promoting the repair of damaged joint tissue, it is envisioned that not only will there be symptomatic relief, but also the potential for fundamental disease modification.

Moving forward, it is anticipated that Stem Cell Therapy will become a more accessible and practical treatment, significantly enhancing the quality of daily life for most patients with rheumatoid arthritis. We at 23Century remain hopeful that, with continued research advancements, Stem Cell Therapy will become widely adopted and established as a new, definitive treatment option for rheumatoid arthritis in the future.

Contact Us
Literatur Referensi